Population Pharmacokinetic/Pharmacodynamic Modelling of Dipeptidyl Peptidase IV Inhibitors Cornelia B. Landersdorfer Commentary 05 May 2015 Pages: 673 - 675
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir Brian J. KirbyWilliam T. SymondsAnita A. Mathias Review Article 31 March 2015 Pages: 677 - 690
Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease André J. Scheen Review Article 25 March 2015 Pages: 691 - 708
Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature Stefan WolkingElke SchaeffelerAnne T. Nies Review Article 10 April 2015 Pages: 709 - 735
Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus Silke RetlichVincent DuvalAlexander Staab Original Research Article Open access 31 January 2015 Pages: 737 - 750
Effect of Renal Impairment on the Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase1 (DGAT1) Inhibitor Sachiko MitaDan MeyersJin Chen Original Research Article 28 January 2015 Pages: 751 - 760
Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor Masaru HiranoDan MeyersJin Chen Original Research Article 30 January 2015 Pages: 761 - 770
Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2? Pieter M. M. De KeselWilly E. LambertChristophe P. Stove Original Research Article 21 January 2015 Pages: 771 - 781
Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement Salmaan KanjiMeghan HayesDavid Moher Original Research Article 31 January 2015 Pages: 783 - 795